Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03871153 · ClinicalTrials.gov registry record · Phase 2
Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Greg Durm, MD.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT03871153 is a Phase 2 study that was terminated before completion, run by Greg Durm, MD. The registered enrollment target is 7 participants.
The verdict
NCT03871153, a Phase 2 study, was terminated before completion, sponsored by Greg Durm, MD.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is an open label, multi-institutional, single arm Phase II trial. All patients will be treated with Carboplatin, Paclitaxel, Durvalumab and Radiation. All patients with non-PD after induction therapy who remain surgical candidates will undergo surgical resection 4-12 weeks following induction therapy. After surgical resection, all patients who remain eligible will be treated with adjuvant Durvalumab every 4 weeks for 6 cycles beginning 4-12 weeks after surgical resection.
Interventions
- DRUG Carboplatin
- PROCEDURE Surgical Resection
- DRUG Paclitaxel
- RADIATION Radiation
- DEVICE Durvalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2019-08-02 |
| Est. Completion | 2022-03-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03871153
The ClinicalTrials.gov registry entry for NCT03871153 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Greg Durm, MD, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT03871153 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03871153 about?
NCT03871153 is a clinical study titled "Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer". This is an open label, multi-institutional, single arm Phase II trial. All patients will be treated with Carboplatin, Paclitaxel, Durvalumab and Radiation. All patients with non-PD after induction therapy who remain surgical candidates will undergo surgical resection 4-12 weeks following induction t...
What is the current status of trial NCT03871153?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2019-08-02. Estimated completion is 2022-03-09.
What interventions are being tested in trial NCT03871153?
The interventions under investigation include: Carboplatin (DRUG), Surgical Resection (PROCEDURE), Paclitaxel (DRUG), Radiation (RADIATION), Durvalumab (DEVICE).
Who is sponsoring clinical trial NCT03871153?
This trial is sponsored by Greg Durm, MD, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.